CONTENTS

SHORT COMMUNICATIONS

Delayed Elimination of SN-38 in Cancer Patients with Severe Renal Failure. Ken-ichi Fujita, Yu Suzuki, Kei-ichi Miwa, Yoko Akiyama, Miako Sugiyma, Kaori Kawara, Hiroo Ishida, Keishi Yamashita, Keiko Mizuno, Shigehira Saji, Wataru Ichikawa, Wataru Yamamoto, Fumio Nagashima, Toshimichi Miyake, Masaru Narabayashi, Yuichi Ando, Takashi Hirose, and Yasutsuna Sasaki 161

Altered Cytochrome P450 Expression in Mice during Pregnancy. Kwi Hye Koh, Hui Xie, Ai-Ming Yu, and Hyunyoung Jeong 165

Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions. Eleanor J. Guest, Leon Aarons, J. Brian Houston, Amin Rostami-Hodjegan, and Aleksandra Galetin 170

ARTICLES

Morphine Brain Pharmacokinetics at Very Low Concentrations Studied with Accelerator Mass Spectrometry and Liquid Chromatography-Tandem Mass Spectrometry. Muhammad Waqas Sadiq, Mehran Salehpour, Niklas Forsgard, Göran Possnert, and Margareta Hammarlund-Udenaes 174

Human CYP2S1 Metabolizes Cyclooxygenase- and Lipooxygenase-Derived Eicosanoids. Peter Biu, Satoshi Imadzumi, Sudheer Reddy Beedanagari, Srinivasa T. Reddy, and Oliver Hankinson 180

CYP4F Enzymes Are Responsible for the Elimination of Fingolimod (FTY720), a Novel Treatment of Relapsing Multiple Sclerosis. Yi Jin, Markus Zollinger, Hubert Borell, Alfred Zimmerlin, and Christopher J. Patten 191

Absorption and Disposition of the Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) in Healthy Volunteers: A Case of Xenobiotic Biotransformation Following Endogenous Metabolic Pathways. Markus Zollinger, Hans-Peter Gschwind, Yi Jin, Claudia Sayer, Frédéric Zécri, and Stefan Hartmann 199

Glutaredoxin and Thioredoxin Can Be Involved in Producing the Pharmacologically Active Metabolite of a Thienopyridine Antiplatelet Agent, Prasugrel. Katsunobu Hagihara, Miho Kazui, Atsushi Kurihara, Kazuishi Kubota, and Toshihiko Ikeda 208

Disposition and Metabolism of [14C]SB-649868, an Orexin 1 and 2 Receptor Antagonist, in Humans. Cecilia Renzulli, Mike Nash, Mark Wright, Steven Thomas, Stefano Zamuner, Marco Pellegrini, Paolo Bettinelli, and Gary Boyle 215

Metabolism and Disposition of 14C-Labeled Pelaglutazar in Humans. Lifei Wang, Carey Munsick, Sean Chen, Samuel Bonacorsi, Peter T. Cheng, W. Griffith Humphreys, and Donglu Zhang 228


Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model. Martin N. Fransson, Henrik Grip, Jan-Eric Litton, and Lena E. Friberg 247

Tissue Distribution and Elimination of [14C]Apixaban in Rats. Lifei Wang, Kan He, Brad Maxwell, Scott

Continued on next page
Brain Tissue Binding of Drugs: Evaluation and Validation of Solid Supported Porcine Brain Membrane Vesicles (TRANSIL) as a Novel High-Throughput Method. Raffaele Longhi, Silvia Corbioli, Stefano Fontana, Federica Vinco, Simone Braggio, Lydia Helmdach, Jürgen Schiller, and Hinnerk Boriss .......... 312

Correlation between Bilirubin Glucuronidation and Estradiol-3-Gluronidation in the Presence of Model UDP-Glucuronosyltransferase 1A1 Substrates/Inhibitors. Jin Zhou, Timothy S. Tracy, and Rory P. Remmel ............. 322


Identification and Validation of Novel Human Pregnan X Receptor Activators among Prescribed Drugs via Ligand-Based Virtual Screening. Yongmei Pan, Linhao Li, Gregory Kim, Sean Ekins, Hongbing Wang, and Peter W. Swaan ... 337

Inactivation of Cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a Thiophene-Containing Anticancer Drug. Hsia-lien Lin, Haoming Zhang, Christine Medower, Paul F. Hollenberg, and William W. Johnson .............. 345

ERRATUM
Correction to “Identification of Clinically Utilized Drugs that Activate Pregnane X Receptors” ... 351

Contents (cont’d.)

J. Grossman, Larry M. Tremaine, W. Griffith Humphreys, and Donglu Zhang .............. 256

Attenuation of Intestinal Absorption by Major Efflux Transporters: Quantitative Tools and Strategies Using a Caco-2 Model. Xuena Lin, Suzanne Skolnik, Xiaohui Chen, and Jianling Wang ...... 265

The Utility of In Vitro Data in Making Accurate Predictions of Human P-Glycoprotein-Mediated Drug-Drug Interactions: A Case Study for AZD5672. Robert Elsby, Michael Gillen, Caroline Butters, Gemma Imisson, Pradeep Sharma, Veronica Smith, and Dominic D. Surry ........ 275

Tissue Distribution and Characterization of Drug-Related Material in Rats and Dogs after Repeated Oral Administration of Casopitant. Sabrina Pagliaruso, Silvia Martinucci, Ellentia Bordini, Lidia Miraglia, Domenico Cufari, Luca Ferrari, and Mario Pellegratti .......... 283


Brain Tissue Binding of Drugs: Evaluation and Validation of Solid Supported Porcine Brain Membrane Vesicles (TRANSIL) as a Novel High-Throughput Method. Raffaele Longhi, Silvia Corbioli, Stefano Fontana, Federica Vinco, Simone Braggio, Lydia Helmdach, Jürgen Schiller, and Hinnerk Boriss .......... 312

Correlation between Bilirubin Glucuronidation and Estradiol-3-Gluronidation in the Presence of Model UDP-Glucuronosyltransferase 1A1 Substrates/Inhibitors. Jin Zhou, Timothy S. Tracy, and Rory P. Remmel ............. 322


Identification and Validation of Novel Human Pregnan X Receptor Activators among Prescribed Drugs via Ligand-Based Virtual Screening. Yongmei Pan, Linhao Li, Gregory Kim, Sean Ekins, Hongbing Wang, and Peter W. Swaan ... 337

Inactivation of Cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a Thiophene-Containing Anticancer Drug. Hsia-lien Lin, Haoming Zhang, Christine Medower, Paul F. Hollenberg, and William W. Johnson .............. 345

ERRATUM
Correction to “Identification of Clinically Utilized Drugs that Activate Pregnane X Receptors” ... 351

Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: Molecular modeling showing the binding of OSI-930 in the active sites of P450 3A4 (A) and P450 3A5 (B). See the article by Lin et al. on page 345 of this issue.